Objective: The aim of this study was to evaluate the value of each follow-up PET/CT in the clinical assessment of recurrence as well as determining its impact on management in patients with non-Hodgkin lymphoma (NHL).
Patients And Methods: All patients diagnosed with NHL who had at least 1 follow-up PET/CT study, 6 months after primary treatment completion, were included. There were 204 eligible NHL patients with 560 follow-up PET/CT scans.
The role of positron emission tomography (PET) and PET/computed tomography (CT) in the management of pancreatic cancer patients has not been clearly established. Although value of PET/CT in the staging of pancreatic cancer is still being debated, several studies pointed to its superior role in determining therapy response, recurrence detection, and survival prediction in comparison to conventional imaging including contrast-enhanced CT. This article reviews the current literature on usefulness of PET/CT in the management of pancreatic cancer patients.
View Article and Find Full Text PDF